Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.
McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Srinivas S, Vaishampayan UN, Rha SY, Pal SK, Donskov F, Tantravahi SK, Rini BI, Heng DY, Choueiri TK. McKay RR, et al. Among authors: tantravahi sk. Eur Urol. 2014 Mar;65(3):577-84. doi: 10.1016/j.eururo.2013.08.012. Epub 2013 Aug 15. Eur Urol. 2014. PMID: 23962746 Free PMC article.
A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.
Alimohamed N, Lee JL, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Tantravahi S, Kollmannsberger C, North S, Rini BI, Choueiri TK, Heng DY. Alimohamed N, et al. Clin Genitourin Cancer. 2014 Aug;12(4):e127-31. doi: 10.1016/j.clgc.2013.12.003. Epub 2013 Dec 27. Clin Genitourin Cancer. 2014. PMID: 24485801
First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
Harshman LC, Kroeger N, Rha SY, Donskov F, Wood L, Tantravahi SK, Vaishampayan U, Rini BI, Knox J, North S, Ernst S, Yuasa T, Srinivas S, Pal S, Heng DY, Choueiri TK. Harshman LC, et al. Among authors: tantravahi sk. Clin Genitourin Cancer. 2014 Oct;12(5):335-40. doi: 10.1016/j.clgc.2014.03.003. Epub 2014 Mar 15. Clin Genitourin Cancer. 2014. PMID: 24787966 Free PMC article.
Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors.
Bailey EB, Merriman J, Maughan B, Poole A, Tantravahi SK, Agarwal AM, Batten JA, Patel SB, Pal SK, Stenehjem DD, Agarwal N. Bailey EB, et al. Among authors: tantravahi sk. J Oncol Pharm Pract. 2018 Apr;24(3):190-197. doi: 10.1177/1078155217693426. Epub 2017 Feb 20. J Oncol Pharm Pract. 2018. PMID: 28436250
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.
Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G. Agarwal N, et al. Among authors: tantravahi sk. Clin Genitourin Cancer. 2014 Apr;12(2):130-7. doi: 10.1016/j.clgc.2013.09.002. Epub 2013 Sep 28. Clin Genitourin Cancer. 2014. PMID: 24220220 Free PMC article.
Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2.
Stenehjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, Gill D, Straubhar AM, Agarwal AM, Grossmann KF, Samlowski WE, Redman B, Agarwal N, Alva A. Stenehjem DD, et al. Among authors: tantravahi sk. Cancer Immunol Immunother. 2016 Aug;65(8):941-9. doi: 10.1007/s00262-016-1854-1. Epub 2016 Jun 8. Cancer Immunol Immunother. 2016. PMID: 27277816 Free PMC article.
Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Bailey EB, Tantravahi SK, Poole A, Agarwal AM, Straubhar AM, Batten JA, Patel SB, Wells CE, Stenehjem DD, Agarwal N. Bailey EB, et al. Among authors: tantravahi sk. Clin Genitourin Cancer. 2015 Jun;13(3):e131-7. doi: 10.1016/j.clgc.2014.11.002. Epub 2014 Nov 15. Clin Genitourin Cancer. 2015. PMID: 25497584
41 results